← Eichor
Condition: Flt3 Internal Tandem Duplication Positive Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Flt3 Internal Tandem Duplication Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Phase 1 · 1 location(s) · Shijiazhuang Yiling Pharmaceutical Co. Ltd · NCT07162116MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07463651
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.